Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
FOXO Technologies ( (FOXO) ) has provided an update.
On September 23, 2025, FOXO Technologies appointed Sylwia Nowak Hauman as the new Chief Financial Officer, leveraging her extensive experience in finance and biotech. Additionally, on September 22, 2025, the company amended its Certificate of Incorporation to adjust the terms of its Series A Preferred Stock, impacting voting rights, conversion prices, and dividend payments.
Spark’s Take on FOXO Stock
According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.
FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.
To see Spark’s full report on FOXO stock, click here.
More about FOXO Technologies
FOXO Technologies Inc. operates in the biotechnology and pharmaceutical industry, focusing on innovative finance and administrative leadership. The company is involved in developing and commercializing new technologies, with expertise in both public and private sectors.
Average Trading Volume: 8,882,165
Technical Sentiment Signal: Sell
Current Market Cap: $360.3K
See more insights into FOXO stock on TipRanks’ Stock Analysis page.